Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 30th September 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 5.8% | -7.3% | - |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 5.8% | -7.3% | - |
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Oct 24 2025 | 2025 Q3 | FN, FOUR, FRPT, INSP, MEDP, OPEN, SG | AI, Quality, Shorting, small caps, Speculation | - | The fund declined as speculative, unprofitable small caps surged on AI and quantum themes. Managers describe the market as highly euphoric, reminiscent of 202021. They… |
| Jul 21 2025 | 2025 Q2 | FN, GWRE, HQY, INSP, NSA, RKLB, SG, SKY | Defensive, Long/Short, Quality, valuation |
SKY NSA INSP GWRE HQY |
- |
| Mar 31 2025 | 2025 Q1 | AGYS, BROS, FRPT, GLOB, ITCI, RBC | - | - | - |
| Dec 31 2024 | 2024 Q4 | ACHC, FND, HQY, ICFI, IONQ, PCTY | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q3 |
AIAI has been integrated into RGA's research process through tools like NotebookLM, Gems in Gemini, and Claude Code. The firm views AI as a force multiplier for human judgment rather than a replacement, emphasizing the Kasparov Law principle. They believe the market narrative around AI displacement is swinging to unhelpful extremes, creating investment opportunities. |
Machine Learning Automation Software Productivity Innovation |
Small CapsSmall caps getting strong start in 2026 supported by easing monetary conditions and constructive fiscal backdrop. Small caps more sensitive to economic cyclicality which is overdue for expansion. Expected to grow at better pace than large caps in 2026 after long period of underperformance. |
Value Growth Cyclical Monetary Policy Fiscal Policy | |
| 2025 Q2 |
Long/Short |
|
Quality Growth |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 21, 2025 | Fund Letters | Mick Rasmussen | HQY | HealthEquity, Inc. | Financials | Asset Management & Custody | Bull | New York Stock Exchange | Custody, cybersecurity, Healthcarefinance, Hsas, Operatingleverage | Login |
| Jul 21, 2025 | Fund Letters | Mick Rasmussen | SKY | Champion Homes, Inc. | Consumer Discretionary | Homebuilding | Neutral | New York Stock Exchange | affordability, Housing, Interestrates, Margins, Modularhousing | Login |
| Jul 21, 2025 | Fund Letters | Mick Rasmussen | NSA | National Storage Affiliates Trust | Real Estate | Self-Storage REIT | Bull | New York Stock Exchange | Acquisitions, consolidation, Interestrates, REIT, Selfstorage | Login |
| Jul 21, 2025 | Fund Letters | Mick Rasmussen | INSP | Inspire Medical Systems, Inc. | Health Care | Medical Devices | Bull | New York Stock Exchange | Adoption, innovation, Medicaldevices, Procedures, Sleepapnea | Login |
| Jul 21, 2025 | Fund Letters | Mick Rasmussen | GWRE | Guidewire Software, Inc. | Information Technology | Application Software | Bull | New York Stock Exchange | Cloudmigration, Insurancesoftware, Modernization, SaaS, Switchingcosts | Login |
| TICKER | COMMENTARY |
|---|---|
| FN | Fabrinet Information Technology 1.6 |
| FOUR | Relative weakness was also driven by Shift4 Payments |
| INSP | Inspire Medical had a difficult first three quarters of the year due to challenges rolling out a new version of their product, and delays setting up reimbursement codes and billing software. The stock rebounded somewhat in the fourth quarter, but it wasn't enough to overcome the weakness earlier in the year. Inspire's product offering and differentiation in the market is still a strength, and supportive of continued leadership in a large addressable market, which is why we have stuck with the stock. |
| MEDP | Medpace was the Fund's largest contributor in H1 FY26, having been among its largest detractors over the prior 12 months. Medpace is a US-listed clinical research organisation focused on small biotechnology companies. After four consecutive quarters of elevated project cancellations, Medpace delivered a strong inflection in fundamentals, reporting very robust net bookings growth in Q2 and Q3 FY25, alongside stronger-than-expected guidance for FY26. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||